glp-1 drug prices Novo cuts 70%, but semaglutide revenue could grow in 2026 Market Overview: GLP-1 Agonists and

Researchers are also evaluating retatrutide for type 2 diabetes (TRIUMPH-2), cardiovascular outcomes (TRIUMPH-3), and other conditions such as metabolic dysfunction-associated steatotic liver disease (MASLD)

Exp Clin Endocrinol Diab

Tirzepatides 12.12% forecast CAGR reflects its dual receptor mechanism and superior weight-loss performance, with COFEPRIS granting an obesity label in 2024

Semaglutide (Wegovy) delivers the most impressive outcomes

25 (5), 10751090.e5

The attorneys general identified the following concerns including: Counterfeit semaglutide imported from China, Turkey and India and repackaged as FDA-approved products Online sellers promoting research-only peptides while providing instructions for human injection Consumers mixing raw powders at home, leading to overdoses, contamination and serious adverse events Compounding pharmacies operating around legal boundaries, including insanitary conditions and high-impurity formulations Risks of hospitalization tied to dosing errors and adulterated ingredients The attorneys general asked the FDA and the Department of Homeland Security to take joint action to intercept illegal imports and protect patient safety